Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: Implication for 5-fluorouracil-based chemotherapy

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 325-329

  Lu, Zhihong ^a   Zhang, Ruiwen ^a,c   Carpenter, John T ^b,c   Diasio, Robert B ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEFICIENCY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PHARMACOGENETICS; PRIORITY JOURNAL;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUOROURACIL; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; OXIDOREDUCTASES;

EID: 0031912432     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Diasio, R. B., and Harris B. E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 16: 215-237, 1989.
2. Daher, G. C., Harris, B. E., and Diasio, R. B. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol. Ther., 48: 189-222, 1990.
3. Scrip's Cancer Chemotherapy Report. Scrip World Pharmaceutical News. London: PJB Publications, Ltd., 1996.
4. Allegra, C. J., and Grem, J. L. Antimetabolites. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer-Principles and Practice of Oncology, Ed. 5, pp. 432-451. Philadelphia: J. B. Lippincott, 1997.
5. Schilsky, R. L. Antimetabolites. In: M. C. Perry (ed.), The Chemotherapy Source Book, pp. 306-308. Baltimore: Williams and Wilkins, 1992.
6. Heggie, G. D., Sommadossi, J-P., Cross, D. S., Huster, W. J., and Diasio, R. B. Clinical Pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987.
7. Au, J. L., Rustum, Y. M., Ledesma, E. J., Mittleman, A., and Creaven, P. J. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colon rectal carcinomas. Cancer Res., 42: 2930-2937, 1982.
8. Woodcock, T. M., Martin, D. S., Damin, A. E. M., Kemeny, N. E., and Young, C. W. Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation. Cancer (Phila.), 45: 1135-1143, 1980.
9. Harris, B. E., Song, R., Soong, S-J., and Diasio, R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50: 197-201, 1990.
10. Fleming, R. A., Milano, G., Thyss, A., Etienne, M-C., Renee, N., Schneider, M., and Demard, F. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res., 52: 2899-2902, 1992.
11. Harris, B. E., Song, R., He, Y-J., Soong, S-J., and Diasio, R. B. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase, possible relevance to fluoropyrimidine chemotherapy. Biochem. Pharmacol., 37: 4759-4762, 1988.
12. Zhang, R., and Diasio, R. B. Pharmacologic basis for circadian pharmacodynamics. In: W. J. M. Hrushesky (ed.), Circadian Cancer Therapy, pp. 61-103. Boca Raton, FL: CRC, 1994.
13. Levi, F., Misset, J-L., Brienza, S., Adam, R., Metzger, G., Itzakhi, M., Caussanel, J-P., Kunstlinger, F., Lecouturier, S., Descorps-Declere, A., Jasmin, C., Bismuth, H., and Reinberg, A. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer (Phila.), 69: 893-900, 1992.
14. Tuchman, M., Stoeckeler, J. S., Kiang, D. T., O'Dea, R. F., Rammaraine, M. L., and Mirkin, B. L. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N. Engl. J. Med., 313: 245-249, 1985.
15. Diasio, R. B., Beavers, T. L., and Carpenter, J. T. Familial deficiency of dihydropyrimidine dehydrogenase. J. Clin. Invest., 87: 47-51, 1988.
16. Harris, B. E., Carpenter, J. T., and Diasio, R. B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer (Phila.), 68: 499-501, 1991.
17. Lyss, A. P., Lilenbaum, R. C., Harries, B. E., and Diasio, R. B. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest., 11: 239-240, 1993.
18. Lu, Z., Zhang, R., and Diasio, R. B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res., 53: 5433-5438, 1993.
19. Houyan, P., Gay, C., Chatelut, E., Canal, P., and Milano, G. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J. Natl. Cancer Inst., 85: 1602-1603, 1993.
20. Diasio, R. B., Van Kuilenburg, A. B., Lu, Z., Zhang, R., Van Lenthe, H., Bakker, H. D., and Van Gennip, A. H. Determination of dihydropyrimidine dehydrogenase (DPD) in fibroblasts of a DPD deficient pediatric patient and family members using a polyclonal antibody to human DPD. Adv. Exp. Med. Biol., 370: 7-10, 1994.
21. Takimoto, C., Lu, Z., Zhang, R., Liang, M., Larson, L., Grem, J. L., Allegra, C. L., Diasio, R. B., and Chu, E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin. Cancer Res., 2: 477-481, 1996.
22. Ho, D. H., Townsend, L., Luma, M. A., and Bodely, G. P. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res., 6: 781-784, 1986.
23. Lu, Z., Zhang, R., and Diasio, R. B. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin. Pharmcol. Ther., 58: 512-522, 1995.
24. Chazal, M., Etienne, M. C., Renee, N., Bourgeon, A., Richelme, H., and Milano, G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin. Cancer Res., 2: 507-510, 1996.
25. Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thyss, A., Renee, N., Schneider, M., Demard, F., and Milano, G. A population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol., 12: 2248-2253, 1994.
26. Milano, G., Etienne, M. C., Cassuto-Viguier, E., Thyss, A., Santini, J., Frenay, M., Renee, N., Schneider, M., and Demard, F. Influence of sex and age on fluorouracil clearance. J. Clin. Oncol., 10: 1171-1175, 1992.
27. Vokes, E. E., Mick, R., Kies, M. S., Dolan, M. E., Malone, D., Athanasiadis, I., Haraf, D. J., Kozloff, M., Weichselbaum, R. R., and Ratin, M. J. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J. Clin. Oncol., 14: 1663-1671, 1996.
28. McMurrough, J., and McLeod, H. L. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br. J. Clin. Pharmacol., 41: 425-427, 1996.
29. Etienne, M. C., Milano, G., Renee, N., Lagrange, J. L., Dassonville, O., Thyss, A., Schneider, M., Francois E., Fleming, R., and Demard, F. Population study of dihydropyrimidine dehydrogenase in cancer patients. Bull. Cancer, 82: 705-710, 1995.
30. Sommadossi, J-P., Gewirtz, D. A., Diasio, R. B., Aubert, C., Cano, J. P., and Goldman, I. D. Rapid catabolism of 5-fluorouracil in freshly isolated hepatocytes as analyzed by high performance liquid chromatography. J. Biol. Chem., 257: 8171-8176, 1982.
31. Bradford, M. A. Rapid sensitive method for the quantitation of microgram qualities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 258-254, 1976.
32. Lu, Z., Zhang, R., and Diasio, R. B. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J. Biol. Chem., 267: 17102-17109, 1992.
33. Lu, Z., Zhang, R., and Diasio, R. B. Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver: biochemical and Immunological properties. Biochem. Pharmacol., 46: 945-952, 1993.
34. Jiang, W., Lu, Z., He, Y., and Diasio, R. B. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication for 5-fluorouracil-based chemotherapy. Clin. Cancer Res., 3: 395-399, 1997.